Niclosamide and Bicalutamide CombinationTreatment Overcomes Enzalutamide- andBicalutamide-Resistant Prostate Cancer

[traveller64]

mct.aacrjournals.org/conten...

In summary, our results demonstrate that AR variants, particularly AR-V7, drive bicalutamide resistance. Targeting AR-V7 with

niclosamide can resensitize bicalutamide-resistant cells to bicalutamide treatment. Furthermore, combination of niclosamide

with bicalutamide inhibits enzalutamide-resistant tumor growth,

suggesting that the combination of niclosamide with bicalutamide could provide a potential cost-effective strategy to treat

advanced prostate cancer that fails to respond to enzalutamide

therapy. A clinical trial of niclosamide plus bicalutamide to treat

mCRPC patients is planned.

[GP24]

In this phase I trial they were not successful with niclosamide:

ncbi.nlm.nih.gov/pubmed/298...

The University of California, Davis has two phase I studies with niclosamide recruiting, one with Enzalutamide and one with Abiraterone:

clinicaltrials.gov/ct2/show...

clinicaltrials.gov/ct2/show...

[Hidden in reply to GP24]

I go to a support group in the Sacramento area that has 2 people in one of these trials. I believe they are both in the Niclosamide and Abiraterone trial. Both are doing well.

[GP24 in reply to Hidden]

I found this report about the Abi trial:

ascopubs.org/doi/abs/10.120...

Apparently, they could achieve the required dosis in this trial without toxicity and start with a phase II trial.

[traveller64 in reply to GP24]

Is "Niclosamide/PDMX1001" different than the Niclosamide 400 mg tabs available in the market? I guess the dose they used was 1600 mg *3 daily. I could not find how long was the treatment.

[GP24 in reply to traveller64]

I think the best you can do is to email Dr. Pan and ask for the protocol of the phase II trial. What I found on the internet is this remark:

"escalating doses of oral niclosamide/PDMX1001 (400 mg twice daily, 800 mg twice daily)" in this article:

sciencedirect.com/science/a...

So from that it seems they used the 400 mg tabs and escalated that to four tabs three times daily. Further reports regarding this trial are here:

awesomecapital.wordpress.co...

grantome.com/grant/NIH/R44-...

urotoday.com/conference-hig...

Here is a link to the trial page at UC Davis with contact address:

studypages.com/s/abirateron...

[traveller64]

I am on bicalutamide monotherapy and is interested in this treatment. I understand that niclosamide can resensitize bicalutamide-resistant cells to bicalutamide treatment and this has been proven by clinical trials. What do you think?